Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974)

Simon R. Sinclair, Stefanie A. Kane, Bart J. Van Der Schueren, Alan Xiao, Kenneth J. Willson, Janet Boyle, Inge De Lepeleire, Yang Xu, Lisa Hickey, William S. Denney, Chi Chung Li, John Palcza, Floris H.M. Vanmolkot, Marleen Depré, Anne Van Hecken, M. Gail Murphy, Tony W. Ho, Jay N. De Hoon

Research output: Contribution to journalArticlepeer-review

62 Scopus citations


Aims To evaluate inhibition of capsaicin-induced increase in dermal blood flow (DBF) following telcagepant (MK-0974), a potent and selective orally bioavailable calcitonin gene-related peptide (CGRP) receptor antagonist being developed for the acute treatment of migraine. Methods A three-period crossover study in 12 healthy adult men. Each subject received a single oral dose of telcagepant 300 mg, telcagepant 800 mg or placebo at 0 h, followed 0.5 and 3.5 h later by two topical doses of 300 and 1000 μg capsaicin per 20 μl water-ethanol mixture. Capsaicin was applied at two sites on the volar surface of the subjects' left and right forearms. DBF was assessed by laser Doppler perfusion imaging immediately before ('baseline'), and 0.5 h after each capsaicin application at 1 and 4 h. Plasma samples to determine telcagepant concentrations were collected immediately after laser Doppler perfusion imaging. A pharmacodynamic model was developed to explore the relationship between plasma concentration and inhibition of capsaicin-induced increase in DBF. Results Geometric mean plasma concentrations after dosing with 300 mg and 800 mg telcagepant were 720 and 1146 nm, respectively, at 1 h, vs. 582 and 2548 nm, respectively, at 4 h. The pharmacodynamic model suggested that the EC 90 for telcagepant inhibition of capsaicin-induced increases in DBF was 909 nm. Conclusions Telcagepant inhibits the increases in DBF induced by the topical application of capsaicin on the human forearm. This experimental medicine model may have utility to assist in dose selection for the development of CGRP receptor antagonists.

Original languageEnglish (US)
Pages (from-to)15-22
Number of pages8
JournalBritish Journal of Clinical Pharmacology
Issue number1
StatePublished - Jan 2010
Externally publishedYes


  • Blood flow
  • CGRP
  • Capsaicin
  • Migraine
  • Telcagepant

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974)'. Together they form a unique fingerprint.

Cite this